CJC-1295 & GHRP-6 Blend (10mg)

CJC-1295 & GHRP-6 Peptide Blend

The CJC-1295 & GHRP-6 blend have been posited by researchers to display a synergistic action on cells that participate in the release of growth hormone. More specifically, the mix includes CJC-1295, which appears to be similar in action to growth hormone-releasing hormone (GHRH), and GHRP-6 (Growth Hormone Releasing Peptide 6), which appears to bind to the receptors of the hunger hormone ghrelin.This combination of peptides may possibly increase both the strength and the number of growth hormone signals from somatotroph cells. CJC-1295 appears to target the GHRH receptor pathway, while GHRP-6, is considered by researchers to act on the ghrelin receptor pathway. This may explain why the combination of CJC-1295 and GHRP-6 exhibits potential to interact with somatotroph cells in the pituitary gland and the hypothalamus. Both of these regions in the central nervous system are considered to be comprised of cells that are believed to be important in making and controlling growth hormone synthesis.

CJC-1295 (Mod GRF 1-29) Specifications

Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
Molecular Weight: 3367.954 g/mol
Sequence: H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(Mal)-NH2

Note: DOES NOT CONTAIN DAC

GHRP-6 Specifications

Molecular Formula: C₄₆H₅₆N₁₂O₆
Molecular Weight: 873.032 g/mol
Sequence: His-D-Trp-Ala-Trp-D-Phe-Lys

CJC-1295 & GHRP-6 Blend Research

CJC-1295 (Mod GRF 1-29), also referred to as tetra-substituted GRF (1-29), is a synthetically developed peptide equivalent to the naturally occurring GHRH hormone. It comprises the smallest possible amino acid chain proposed to interact with GHRH receptors and includes the initial 29 amino acids of GHRH. The primary structural distinction between CJC-1295 and its naturally occurring GHRH counterpart lies in four substituted amino acids — specifically at positions 2, 8, 15, and 27 — designed to potentially enhance the peptide’s resistance to degradation by the enzyme dipeptidyl peptidase-4.[1] Researchers noted that “CJC-1295 caused an increase in total pituitary RNA and GH mRNA, suggesting that proliferation of somatotroph cells had occurred, as confirmed by immunohistochemistry images.” CJC-1295 appears to bind to and interact with GHRH receptors in the anterior pituitary gland,[2] potentially maintaining the pulsatile production of growth hormone and supporting overall physiological GH levels.

GHRP-6, by contrast, is an opioid analog of the peptide Met-enkephalin, though researchers suggest it lacks the opioid activity typically associated with enkephalins.[3] It is a synthetic hexapeptide categorized as a hormone-releasing peptide, proposed to exert its effects by binding to ghrelin receptors on pituitary cells and specific hypothalamic neurons, activating the growth hormone secretagogue receptor (GHS-R1a). GHRP-6 appears to act through molecular mimicry of ghrelin, potentially stimulating growth hormone secretion. Given the widespread distribution of growth hormone receptors across many cell types, the effects of GHRP-6 may be broad.[4]

CJC-1295 binding appears to initiate processes leading to growth hormone discharge from vesicles within somatotroph cells, with scientists suggesting the peptide may enhance GH production and elevate “GH concentrations by 2- to 10-fold.”[5] This increase in growth hormone appears sufficiently sustained to elevate levels of key anabolic mediators including insulin-like growth factor 1 (IGF-1), with one research paper reporting a 46% increase in mean growth hormone levels and a 45% increase in mean IGF-1 levels following CJC-1295 exposure in animal research models.[6]

Research on GHRP-6 has examined its potential positive influence across various conditions. The peptide has been primarily investigated in relation to growth hormone deficiency disorders, Multiple Organ Failure (MOF), cachexia, obesity, and eating disorders.[7] GHRP-6 may additionally demonstrate affinity for CD36 receptors, which may serve various functions including potential roles in metabolism, fatty acid scavenging and transport, immune response modulation, phagocytosis regulation, and blood vessel formation.[8] Further scientific exploration is required to validate these hypotheses. Due to its apparent cytoprotective properties, GHRP-6 has been proposed in myocardial infarction research for its potential to reduce scarring in tissues affected by reperfusion injuries. It may also carry potential for anti-aging functions within the cell cycle, alongside possible improvements in sleep quality and cognitive function.

When studied in combination, these peptides appear to act synergistically to elevate growth hormone levels. GHRP-6 appears to maintain a baseline growth hormone level while CJC-1295 primarily stimulates pulsatile GH secretion. Both peptides have additionally been hypothesized to positively influence sleep cycles — and given that the majority of growth and cellular repair occurs during sleep, the peptide combination has been proposed to support cellular regeneration and repair, potentially improving wound healing and nerve tissue protection through sleep quality enhancement.

CJC-1295 and GHRP-6 have also been associated with nervous tissue protection and repair. One study examined the impact of GHRP-6 on the brain’s IGF-1 system in murine models, centering primarily on modulation of the brain’s IGF system given that GH actions are generally considered to be mediated through IGF-1. Researchers reported that one week of GHRP-6 introduction appeared to increase IGF-1 mRNA levels in the hypothalamus, cerebellum, and hippocampus — though not in the cerebral cortex — suggesting that GH and GHRP-6 may enhance IGF-1 expression in specific brain regions. The study also examined IGF receptor and IGFBP-2 expression, reporting no considerable change in activity following peptide introduction. However, phosphorylation of Akt and Bad appeared stimulated in areas where IGF-1 was increased, with researchers noting this implied GH and GHRP-6 may activate phosphatidylinositol kinase intracellular pathways involved in cell survival in response to growth factors. Bad is a pro-apoptotic member of the Bcl-2 protein family recognized as central to cell death regulation, while Akt is a serine/threonine protein kinase involved in multiple cellular processes including glucose metabolism, apoptosis, cell proliferation, transcription, and cell migration. No notable changes were observed in MAPK — a protein kinase specific to serine, threonine, and tyrosine residues — or in glycogen synthase kinase-3beta. The antiapoptotic protein Bcl-2 was elevated in regions showing increased IGF-1, with no corresponding change in the proapoptotic protein Bax — potentially indicating a shift toward cell survival over apoptosis. IGFBP-5, also reported to be involved in neuronal survival, was observed to be elevated predominantly in the hypothalamus, suggesting a potential neuroendocrine role.[9]

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

References